We’re kicking off the New Year with a business development initiative to secure customers in Japan for biotechnology pioneer GALY.
GALY is addressing climate change-induced agricultural ingredient supply problems through plant cell culture-based products.
Its lab-grown cotton, which will hit store shelves soon, was recognised as one of the Best Inventions of 2024 by Time magazine. And the Boston-based company has already signed a $50 million, 10-year deal with Japanese corporation Suzuran Medical to use its lab-grown cotton in healthcare products.
But while the company started out in the textiles industry, it’s capable of producing any type of plant material in its labs. And, last autumn, it raised $33 million from Bill Gates-led Breakthrough Energy Ventures, H&M and Inditex – bringing its total raised so far to $65 million.
Our Tokyo team is now helping to accelerate GALY’s growth in Japan by engaging processed food manufacturers to help solve raw ingredient sourcing challenges linked to factors including climate change.
We’re also introducing the company to potential Japanese partners and investors.
Edgar Poletti, Director of Business Development at GALY, commented: “Intralink’s Tokyo team has hit the ground running and is already setting up meetings with the kind of companies we want to be talking to.
“Japan is not only at the forefront of innovation but a global leader in sustainability, so we’re excited to be in the market and looking forward to making great progress – particularly in certain high-value areas of the food and beverage sector.”
The GALY team
To discuss the prospects for your life sciences business in Japan, contact Sol Bergen-Bartel at sol.bergenbartel@intralinkgroup.com.